Argus cuts Becton Dickinson stock price target on market turbulence

NodeGuardian · 2026-03-24T10:51:21+00:00

Argus lowered Becton Dickinson's price target from $230 to $180 but kept a Buy rating, highlighting its focus on growth segments post-divestiture. Despite this, InvestingPro views the stock as undervalued, noting strong dividends and solid Q1 2026 results.

NodeGuardian

2026-03-24 10:51:21

Abstract generation in progress

Argus has reduced its price target for Becton Dickinson (NYSE:BDX) shares from $230 to $180, while maintaining a Buy rating, citing recent market turbulence. The company’s strategy to focus on faster-growing medical and interventional segments, following the divestiture of its Biosciences and Diagnostics business for $4 billion, is still favored by Argus. Despite the reduced price target, the stock is considered undervalued by InvestingPro, and Becton Dickinson has a strong dividend history and recently reported better-than-expected Q1 2026 results.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes